Possible involvement of platelet activating factor in anaphylaxis of passively sensitised, isolated Guinea pig hearts

A. Tósaki, Matyas Koltai, Pierre Braquet, Laszlo Szekeres

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

There is evidence that cardiac tissue may be a target for antigen/antibody reactions. Platelet activating factor (PAF) is released during anaphylaxis and could mediate cardiac damage. To investigate this, Guinea pigs were passively sensitised by anti-ovalbumin rabbit serum (6 mg·kg-1intravenously) and 24 h later their hearts were excised and isolated according to a working heart preparation technique. After a 20 min equilibration period, anaphylactic challenge was induced by a bolus injection of ovalbumin (2 mg in 0.2 ml buffer) via the side arm of the aortic cannula. Heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LVdp/dtmax) and left ventricular end diastolic pressure (LVEDP) were recorded. After ovalbumin challenge, heart rate and LVEDP were markedly increased, while coronary flow, aortic flow, LVDP, and LVdp/dtmax were profoundly decreased. All these alterations were over within 5 min, and the measured variables returned to approximately the pre-challenge values. BN 52021, a specific PAF receptor antagonist, was dissolved in the perfusion buffer and given in doses of 15, 30 and 60 μmol·litre-1 10 min prior to the induction of anaphylactic challenge until the end of the observation period. BN 52021 inhibited the increase in heart rate and LVEDP and the decrease in coronary and aortic flow, LVDP and LVdp/dtmax in a dose dependent manner. The changes produced by 30 and 60 μmol·litre-1 were statistically significant at the levels of p<0.01 and p<0.001 when compared to the control values. The results obtained indicate that after anaphylactic challenge the isolated, passively sensitised, working Guinea pig heart shows dramatic changes in dynamic variables. The protective effect of BN 52021 suggests that PAF is involved as a mediator in cardiac anaphylaxis, and PAF antagonists may have therapeutic value against cardiac symptoms during anaphylactic shock.

Original languageEnglish
Pages (from-to)715-722
Number of pages8
JournalCardiovascular Research
Volume23
Issue number8
DOIs
Publication statusPublished - Jan 1 1989

Fingerprint

ginkgolide B
Platelet Activating Factor
Ovalbumin
Anaphylaxis
Ventricular Pressure
Guinea Pigs
Heart Rate
Blood Pressure
Buffers
Antigen-Antibody Reactions
Perfusion
Observation
Rabbits
Injections
Serum

Keywords

  • Anaphylaxis
  • Guinea pig heart
  • PAF receptor antagonist

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Possible involvement of platelet activating factor in anaphylaxis of passively sensitised, isolated Guinea pig hearts. / Tósaki, A.; Koltai, Matyas; Braquet, Pierre; Szekeres, Laszlo.

In: Cardiovascular Research, Vol. 23, No. 8, 01.01.1989, p. 715-722.

Research output: Contribution to journalReview article

Tósaki, A. ; Koltai, Matyas ; Braquet, Pierre ; Szekeres, Laszlo. / Possible involvement of platelet activating factor in anaphylaxis of passively sensitised, isolated Guinea pig hearts. In: Cardiovascular Research. 1989 ; Vol. 23, No. 8. pp. 715-722.
@article{84c3eea5cad54f92852babbad0039ced,
title = "Possible involvement of platelet activating factor in anaphylaxis of passively sensitised, isolated Guinea pig hearts",
abstract = "There is evidence that cardiac tissue may be a target for antigen/antibody reactions. Platelet activating factor (PAF) is released during anaphylaxis and could mediate cardiac damage. To investigate this, Guinea pigs were passively sensitised by anti-ovalbumin rabbit serum (6 mg·kg-1intravenously) and 24 h later their hearts were excised and isolated according to a working heart preparation technique. After a 20 min equilibration period, anaphylactic challenge was induced by a bolus injection of ovalbumin (2 mg in 0.2 ml buffer) via the side arm of the aortic cannula. Heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LVdp/dtmax) and left ventricular end diastolic pressure (LVEDP) were recorded. After ovalbumin challenge, heart rate and LVEDP were markedly increased, while coronary flow, aortic flow, LVDP, and LVdp/dtmax were profoundly decreased. All these alterations were over within 5 min, and the measured variables returned to approximately the pre-challenge values. BN 52021, a specific PAF receptor antagonist, was dissolved in the perfusion buffer and given in doses of 15, 30 and 60 μmol·litre-1 10 min prior to the induction of anaphylactic challenge until the end of the observation period. BN 52021 inhibited the increase in heart rate and LVEDP and the decrease in coronary and aortic flow, LVDP and LVdp/dtmax in a dose dependent manner. The changes produced by 30 and 60 μmol·litre-1 were statistically significant at the levels of p<0.01 and p<0.001 when compared to the control values. The results obtained indicate that after anaphylactic challenge the isolated, passively sensitised, working Guinea pig heart shows dramatic changes in dynamic variables. The protective effect of BN 52021 suggests that PAF is involved as a mediator in cardiac anaphylaxis, and PAF antagonists may have therapeutic value against cardiac symptoms during anaphylactic shock.",
keywords = "Anaphylaxis, Guinea pig heart, PAF receptor antagonist",
author = "A. T{\'o}saki and Matyas Koltai and Pierre Braquet and Laszlo Szekeres",
year = "1989",
month = "1",
day = "1",
doi = "10.1093/cvr/23.8.715",
language = "English",
volume = "23",
pages = "715--722",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Possible involvement of platelet activating factor in anaphylaxis of passively sensitised, isolated Guinea pig hearts

AU - Tósaki, A.

AU - Koltai, Matyas

AU - Braquet, Pierre

AU - Szekeres, Laszlo

PY - 1989/1/1

Y1 - 1989/1/1

N2 - There is evidence that cardiac tissue may be a target for antigen/antibody reactions. Platelet activating factor (PAF) is released during anaphylaxis and could mediate cardiac damage. To investigate this, Guinea pigs were passively sensitised by anti-ovalbumin rabbit serum (6 mg·kg-1intravenously) and 24 h later their hearts were excised and isolated according to a working heart preparation technique. After a 20 min equilibration period, anaphylactic challenge was induced by a bolus injection of ovalbumin (2 mg in 0.2 ml buffer) via the side arm of the aortic cannula. Heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LVdp/dtmax) and left ventricular end diastolic pressure (LVEDP) were recorded. After ovalbumin challenge, heart rate and LVEDP were markedly increased, while coronary flow, aortic flow, LVDP, and LVdp/dtmax were profoundly decreased. All these alterations were over within 5 min, and the measured variables returned to approximately the pre-challenge values. BN 52021, a specific PAF receptor antagonist, was dissolved in the perfusion buffer and given in doses of 15, 30 and 60 μmol·litre-1 10 min prior to the induction of anaphylactic challenge until the end of the observation period. BN 52021 inhibited the increase in heart rate and LVEDP and the decrease in coronary and aortic flow, LVDP and LVdp/dtmax in a dose dependent manner. The changes produced by 30 and 60 μmol·litre-1 were statistically significant at the levels of p<0.01 and p<0.001 when compared to the control values. The results obtained indicate that after anaphylactic challenge the isolated, passively sensitised, working Guinea pig heart shows dramatic changes in dynamic variables. The protective effect of BN 52021 suggests that PAF is involved as a mediator in cardiac anaphylaxis, and PAF antagonists may have therapeutic value against cardiac symptoms during anaphylactic shock.

AB - There is evidence that cardiac tissue may be a target for antigen/antibody reactions. Platelet activating factor (PAF) is released during anaphylaxis and could mediate cardiac damage. To investigate this, Guinea pigs were passively sensitised by anti-ovalbumin rabbit serum (6 mg·kg-1intravenously) and 24 h later their hearts were excised and isolated according to a working heart preparation technique. After a 20 min equilibration period, anaphylactic challenge was induced by a bolus injection of ovalbumin (2 mg in 0.2 ml buffer) via the side arm of the aortic cannula. Heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LVdp/dtmax) and left ventricular end diastolic pressure (LVEDP) were recorded. After ovalbumin challenge, heart rate and LVEDP were markedly increased, while coronary flow, aortic flow, LVDP, and LVdp/dtmax were profoundly decreased. All these alterations were over within 5 min, and the measured variables returned to approximately the pre-challenge values. BN 52021, a specific PAF receptor antagonist, was dissolved in the perfusion buffer and given in doses of 15, 30 and 60 μmol·litre-1 10 min prior to the induction of anaphylactic challenge until the end of the observation period. BN 52021 inhibited the increase in heart rate and LVEDP and the decrease in coronary and aortic flow, LVDP and LVdp/dtmax in a dose dependent manner. The changes produced by 30 and 60 μmol·litre-1 were statistically significant at the levels of p<0.01 and p<0.001 when compared to the control values. The results obtained indicate that after anaphylactic challenge the isolated, passively sensitised, working Guinea pig heart shows dramatic changes in dynamic variables. The protective effect of BN 52021 suggests that PAF is involved as a mediator in cardiac anaphylaxis, and PAF antagonists may have therapeutic value against cardiac symptoms during anaphylactic shock.

KW - Anaphylaxis

KW - Guinea pig heart

KW - PAF receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=85047676471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047676471&partnerID=8YFLogxK

U2 - 10.1093/cvr/23.8.715

DO - 10.1093/cvr/23.8.715

M3 - Review article

C2 - 2557156

AN - SCOPUS:85047676471

VL - 23

SP - 715

EP - 722

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 8

ER -